Developmental Medicine & Child Neurology

Elevance Health and AADMD Launch Bold Initiative to Broadly Expand Physician Training on the Care of People with Intellectual and Developmental Disabilities

Retrieved on: 
Wednesday, November 1, 2023
Nursing, People with Disabilities, Practice Management, Other Health, Other Education, General Health, University, Consumer, Health, Education, Knowledge, Spectrum, University of Louisville School of Medicine, Request for proposal, Physician, Intellectual, Immersion, Learning, Rehabilitation, Life expectancy, Curriculum, Down syndrome, American Academy, Developmental Medicine & Child Neurology, Health equity, IDD, RFP, Cerebral palsy, Disability, Elevance Health, Investment, Patient, Pharmaceutical industry, Dentistry

NICHE—Medical was founded by the American Academy of Developmental Medicine and Dentistry (AADMD) in 2009 to provide training to medical students on the care of individuals with IDD.

Key Points: 
  • NICHE—Medical was founded by the American Academy of Developmental Medicine and Dentistry (AADMD) in 2009 to provide training to medical students on the care of individuals with IDD.
  • Through a focus on health equity and the social drivers of health, the project centers people with IDD.
  • With Elevance Health funding and support, AADMD will disburse grants to 28 medical schools over the next five years to support IDD curriculum implementation efforts.
  • This will more than double the number of medical schools that offer training on serving patients with IDD.

Cerebral Palsy Alliance Research Foundation Funding Registry Study for Arabic-Speaking Countries

Retrieved on: 
Friday, October 6, 2023
Partnership, Cerebral Palsy Alliance, Multimedia, Public, American Academy, Prevalence, Ain Shams University Faculty of Medicine, Standard of care, Developmental Medicine & Child Neurology, Education, Cerebral palsy, World Cerebral Palsy Day, Science, Registry, Patient, Residential care

NEW YORK, Oct. 6, 2023 /PRNewswire-PRWeb/ -- In honor of World Cerebral Palsy Day, Cerebral Palsy Alliance Research Foundation (CPARF) proudly announces its first-ever funding of a fully international grant through its partnership with the American Academy of Cerebral Palsy and Developmental Medicine. The $25,000 award will fund a feasibility study to develop a multicenter cerebral palsy registry in Arabic-speaking countries.

Key Points: 
  • NEW YORK, Oct. 6, 2023 /PRNewswire-PRWeb/ -- In honor of World Cerebral Palsy Day, Cerebral Palsy Alliance Research Foundation (CPARF) proudly announces its first-ever funding of a fully international grant through its partnership with the American Academy of Cerebral Palsy and Developmental Medicine.
  • The $25,000 award will fund a feasibility study to develop a multicenter cerebral palsy registry in Arabic-speaking countries.
  • Cerebral Palsy Alliance Research Foundation is a nonprofit organization that funds US-based research to change what's possible for people with cerebral palsy, implements proven science, empowers people through education, and advances technology benefiting all disabled people worldwide.
  • Jocelyn Cohen, Cerebral Palsy Alliance Research Foundation, 646.340.1208, [email protected] , https://www.cparf.org
    View original content to download multimedia: https://www.prweb.com/releases/cerebral-palsy-alliance-research-foundati...

Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII

Retrieved on: 
Thursday, June 22, 2023
Medicine, Cataplexy, Senior, Idiopathic hypersomnia, Internal medicine, Narcolepsy, EDS, Pediatrics, PLLC, Pulmonology, Webcast, Neurology, Commercial, Hospital, FDA, Developmental Medicine & Child Neurology, Pharmaceutical industry, Child

LUMRYZ was approved by the U.S. Food & Drug Administration (FDA) in May 2023 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

Key Points: 
  • LUMRYZ was approved by the U.S. Food & Drug Administration (FDA) in May 2023 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
  • Renowned sleep specialists will include:
    Dr. Anne Marie Morse is a board-certified neurologist and trained sleep medicine specialist.
  • Dr. Thomas Stern completed board certification in five different medical specialties including internal medicine, pediatrics, pulmonary medicine, critical care medicine and sleep medicine.
  • A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

Avadel Pharmaceuticals Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-at-Bedtime Oxybate Dosing for Narcolepsy

Retrieved on: 
Tuesday, June 13, 2023
Narcolepsy, Cataplexy, Doctor of Pharmacy, Senior, Gamma-Hydroxybutyric acid, Geisinger Medical Center, DCE, Discrete, Anxiety, Quality of life, Advances in Therapy, Patient, Somnolence, Neurology, Sodium, Developmental Medicine & Child Neurology, Pharmaceutical industry, Medical imaging, Child

The paper, titled “Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment,” was published in Advances in Therapy and can be accessed here .

Key Points: 
  • The paper, titled “Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment,” was published in Advances in Therapy and can be accessed here .
  • “Sodium oxybate has been recognized as a standard of care to treat narcolepsy for more than 20 years, but, until recently, has required two nighttime doses for sufficient therapy.
  • These data underscore the long unmet need for an oxybate treatment that does not require middle-of-the-night dosing.
  • “These data provide insight that the most important driver of oxybate choice is dosing and not sodium content.”

Sleep Consortium Launches Sleep Patient Data Collection Initiative to Accelerate Therapeutic Development

Retrieved on: 
Tuesday, May 23, 2023
Consortium, Kleine–Levin syndrome, SC, Narcolepsy, Data collection, Research, Children's Hospital, Patient, Chairperson, Somnolence, Neurology, Jazz Pharmaceuticals, Hospital, Idiopathic hypersomnia, Phenotype, Developmental Medicine & Child Neurology, Global Genes, Disease, Pharmaceutical industry, Sleep, Child

"The Sleep Consortium takes a bold new approach to sleep research putting the patient in the center of its efforts. This initiative demands that the patient be the driver of new research considerations, have ownership of their own data, and serve as an invaluable partner to researchers internationally. This novel approach will leverage advanced technologies to further our understanding of sleep-wake disorders by starting with the debilitating symptom of excessive daytime sleepiness and identifying all the faces of patients who are suffering from it to better define the roads that lead to the development, consequence, and association with excessive daytime sleepiness." --- Anne Marie Morse, Director of Child Neurology and Pediatric Sleep Medicine, Geisinger, Janet Weis Children's Hospital and Sleep Consortium Scientific Advisor.

Key Points: 
  • Sleep Consortium and RARE-X, the Global Genes research program and patient-owned data collection platform, to collaborate on the Sleep Data Collection Initiative to accelerate the development of effective treatments for central disorders of hypersomnolence (CDoH) and related conditions.
  • ALISO VIEJO, Calif., May 23, 2023 /PRNewswire-PRWeb/ -- Sleep Consortium (SC) and RARE-X, the Global Genes research program and patient-owned data collection platform, today announced a collaboration to launch the Sleep Data Collection Initiative aimed at accelerating the development of effective treatments for central disorders of hypersomnolence (CDoH) and related conditions.
  • Phase 1 of the Sleep Data Collection Initiative has four main objectives: bring together a multi-disciplinary workgroup to prioritize sleep domains, develop an expanded sleep-focused data model, create a sleep patient community data collection portal, and the publication of a white paper detailing Phase 1 outcomes.
  • "We are thrilled to be partnering with the Sleep Consortium on this patient-centered initiative that promises to accelerate therapeutic development for central disorders of hypersomnolence.

900 Oral health care provider viewpoints inform latest NCD recommendations on Medicaid, Medicare

Retrieved on: 
Wednesday, April 5, 2023
Learning, Developmental Medicine & Child Neurology, Xestia castanea, Dental care, Office of Inspector General, U.S. Department of Health and Human Services, Centers for Medicare & Medicaid Services, Disability, Human services, Policy, Ageing, Forest Law Enforcement and Governance Program, American Academy, OHC, Disability studies, National Council on Disability, NCD, Intellectual, Congress, Student, Data, National Council, Council, Patient, Health, Dentistry, Health insurance, Medicaid, Medicare

Incentivizing Oral Health Care Providers to Treat Patients with Intellectual and Developmental Disabilities provides additional insights into sources and solutions regarding the difficulties of adults with I/DD in accessing quality, appropriate, and timely oral health care (OHC) services.

Key Points: 
  • Incentivizing Oral Health Care Providers to Treat Patients with Intellectual and Developmental Disabilities provides additional insights into sources and solutions regarding the difficulties of adults with I/DD in accessing quality, appropriate, and timely oral health care (OHC) services.
  • Last year, NCD published Medicaid Oral Health Coverage for Adults with Intellectual & Developmental Disabilities – A Fiscal Analysis , providing the initial results of its analysis into how to improve oral health outcomes for people with I/DD.
  • Medicare and Medicaid programs do not support dental care for adults with I/DD.
  • Dental and medical systems of health care do not support integrated health care models for people with I/DD.

NRMP® Celebrates Match Day by Publishing the Results of a Record-Breaking 2023 Main Residency Match®

Retrieved on: 
Friday, March 17, 2023
Acceptance, Emergency medicine, Pediatrics, Obstetrics, Anesthesiology, Face, Obstetrics and gynaecology, Radiology, MBA, History, Competition (economics), BSN, Family medicine, Cardiothoracic surgery, Child, DO, National Resident Matching Program, Interventional radiology, NRMP, MD, Patient, Physician, Pathology, Doctor of Health Science, Internal medicine, Vascular surgery, Physical medicine and rehabilitation, Otorhinolaryngology, Neurology, IMG, Anne Ferguson-Smith, Internship, Integration, Orthopedic surgery, Developmental Medicine & Child Neurology, Nursing, Health insurance, Dentistry, SOAP, Psychiatry, Match, Gynaecology, Surgery

WASHINGTON, March 17, 2023 /PRNewswire/ -- The National Resident Matching Program® (NRMP®) celebrates the landmark milestone that is "Match Day" for the 2023 Main Residency Match with residency applicants, training programs, medical schools, and the medical education community.

Key Points: 
  • WASHINGTON, March 17, 2023 /PRNewswire/ -- The National Resident Matching Program® (NRMP®) celebrates the landmark milestone that is "Match Day" for the 2023 Main Residency Match with residency applicants, training programs, medical schools, and the medical education community.
  • "The 2023 Main Residency Match proved once again to be a highly successful Match with outstanding results for participants.
  • There were 48,156 total applicants registered in the 2023 Main Residency Match, an increase of 481 applicants over last year.
  • SOAP results will be available in the 2023 Main Residency Match Results and Data Book, which is published in the Spring.

Cognoa Appoints Pediatric Neurologist and AI in Healthcare Pioneer Dr. Sharief Taraman as CEO to Spearhead the Next Stage of the Company's Growth

Retrieved on: 
Monday, November 14, 2022
ADHD, Developmental Medicine & Child Neurology, Autism, Informatics, Pediatrics, American Board of Commissioners for Foreign Missions, Stanford University, PALO, Orange County, American Board of Preventive Medicine, University of California, Irvine School of Medicine, Contraindication, Research, Leadership, CHOC, University, FDA, Medical device, AAP, Technology Innovation Institute, Psychiatry, Patient, Pediatric Neurology, Disney family, Division, CEO, Risk, ASD, American Board of Psychiatry and Neurology, Diagnosis, Speech, American Academy, International Society, Language, Medicine, Engineering, Child, Neurology

PALO ALTO, Calif., Nov. 14, 2022 /PRNewswire/ -- Cognoa, a pediatric behavioral health company, today announced the appointment of Dr. Sharief Taraman as Chief Executive Officer. Dr. Taraman previously served as Cognoa's Chief Medical Officer and brings nearly two decades of clinical specialization in neurodevelopmental conditions, clinical informatics, and business acumen.

Key Points: 
  • "I am excited and honored to be tasked with leading the company at this significant stage as we gear up for commercialization of our first product," said Dr. Sharief Taraman, CEO of Cognoa.
  • Canvas Dx serves precisely this purpose, helping providers to diagnose or rule out autism in more children sooner.
  • "Together with Sharief, we have built our first device based on multidimensional behavioral data, backed by groundbreaking AI.
  • The device is not intended for use as a stand-alone diagnostic device but as an adjunct to the diagnostic process.

Cognoa Appoints Pediatric Neurologist and AI in Healthcare Pioneer Dr. Sharief Taraman as CEO to Spearhead the Next Stage of the Company's Growth

Retrieved on: 
Monday, November 14, 2022
ADHD, Developmental Medicine & Child Neurology, Autism, Informatics, Pediatrics, American Board of Commissioners for Foreign Missions, Stanford University, PALO, Orange County, American Board of Preventive Medicine, University of California, Irvine School of Medicine, Contraindication, Research, Leadership, CHOC, University, FDA, Medical device, AAP, Technology Innovation Institute, Psychiatry, Patient, Pediatric Neurology, Disney family, Division, CEO, Risk, ASD, American Board of Psychiatry and Neurology, Diagnosis, Speech, American Academy, International Society, Language, Medicine, Engineering, Child, Neurology

PALO ALTO, Calif., Nov. 14, 2022 /PRNewswire/ -- Cognoa, a pediatric behavioral health company, today announced the appointment of Dr. Sharief Taraman as Chief Executive Officer. Dr. Taraman previously served as Cognoa's Chief Medical Officer and brings nearly two decades of clinical specialization in neurodevelopmental conditions, clinical informatics, and business acumen.

Key Points: 
  • "I am excited and honored to be tasked with leading the company at this significant stage as we gear up for commercialization of our first product," said Dr. Sharief Taraman, CEO of Cognoa.
  • Canvas Dx serves precisely this purpose, helping providers to diagnose or rule out autism in more children sooner.
  • "Together with Sharief, we have built our first device based on multidimensional behavioral data, backed by groundbreaking AI.
  • The device is not intended for use as a stand-alone diagnostic device but as an adjunct to the diagnostic process.

CHOP Study Explores the Use of Telemedicine in Child Neurology in Largest Study to Date

Retrieved on: 
Friday, September 16, 2022
Online, Adult, Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Developmental Medicine & Child Neurology, Children's Hospital of Philadelphia, University, COVID-19, National, MD, Disability in Canada, Hospital, Telehealth, CHOP, Population, Attention deficit hyperactivity disorder predominantly inattentive, Health, Intellectual, Philadelphia, Therapy, Patient, National Institute of Neurological Disorders and Stroke, Epilepsy, Prussia, Perelman School of Medicine at the University of Pennsylvania, ENGIN, Neurology, Research, Observational study, Lists of diseases, Medicine, Movement disorders, National Center for Spinal Disorders, National Institute, Medical device, Pharmaceutical industry, Child, Stroke, Translational medicine

PHILADELPHIA, Sept. 16, 2022 /PRNewswire/ -- Researchers from the Epilepsy Neurogenetics Initiative (ENGIN) at Children's Hospital of Philadelphia (CHOP) found that across nearly 50,000 visits, patients continued to use telemedicine effectively even with the reopening of outpatient clinics a year after the onset of the COVID-19 pandemic. However, prominent barriers for socially vulnerable families and racial and ethnic minorities persist, suggesting more work is required to reach a wider population with telemedicine.

Key Points: 
  • The findings, which represent the largest study of telemedicine in child neurology to date, were published today by the journal Developmental Medicine & Child Neurology .
  • In a prior study published by Neurology in 2020 , CHOP researchers found that patients and clinicians had a high rate of satisfaction with telemedicine and many on both sides were interested in using telemedicine for future visits.
  • To that end, the study team wanted to determine the long-term impact of telemedicine on child neurology care during the COVID-19 pandemic, factoring in the reopening of outpatient clinics.
  • Kaufman et al, "Child neurology telemedicine: analyzing 14 820 patient encounters during the first year of the COVID-19 pandemic."